Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Imperial College London
With
Medical Research Council
Imperial College Healthcare NHS Trust
University College, London
Queen Mary University of London
GlaxoSmithKline
University of Cambridge
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or Female, aged 18-65
Able to give informed consent
Diagnosis of MS according to to the revised McDonald's criteria (Polman et al. Ann Neurol 2005)
Relapsing-remitting or secondary progressive MS form
Disease duration ≤15 years from diagnosis
Expanded disability status scale (EDSS) score 2.0 to 6.0 at screening evaluation
Highly active and/or treatment-refractory MS activity defined as:
1. Two or more clinical exacerbations in the previous 12 months, regardless of treatment; OR:
2. One clinical exacerbation and sustained increase in EDSS of at least 1 point in the previous 12 months after receiving immune-modifying treatment, OR:
3. Evidence of gadolinium (contrast)-enhancement or increase of T2 lesion load at MRI after receiving immune-modifying treatment. OR
4. Not tolerating or not wishing to receive any of the available immune-modifying treatments and meeting one of the stated criteria (b or c) for MS activity in treated subjects (1 relapse and increase in EDSS of at least 1 point in the previous 12 months; or evidence of contrast-enhancement or increase of T2 lesion load at MRI).
You may not be if
Contraindication to MRI including but not limited to intracranial aneurism clips (except Sugita), history of intra-orbital metal fragments that have not been removed by an MD (as confirmed by orbital X-Ray), pacemaker and non-MR compatible heart valves, inner ear implants, history of claustrophobia or subject feels unable to lie still on their back for a period of 1.5 hours in the MRI scanner.
If female, positive urine pregnancy test
History or presence of renal impairment (e.g. serum creatinine clearance less than 30ml/min)
Inability to give informed consent/comply with study procedures
Clareo Health | Patient Research Cohort: Rapidly Evolving Multiple Sclerosis
